Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 3, 2002 - Issue 8
Submit an article Journal homepage
109
Views
30
CrossRef citations to date
0
Altmetric
Miscellaneous

The evolution and role of macrolides in infectious diseases

Joseph M Blondeau Department of Clinical Microbiology, Royal University Hospital, 103 Hospital Drive, Saskatoon, Saskatchewan, Canada, S7N 0W8, Tel: +1 306 655 6943; Fax: +1 306 655 6947;, E-mail: [email protected]
Pages 1131-1151 | Published online: 25 Feb 2005

Bibliography

  • KIRST HA, SIDES GD: New directions for macrolide antibiotics: structure modifications and in vitro activity. Antimicrob. Agents Chemother. (1989) 33:1413–1418.
  • DREW RH, GALLIS HA: Azithromycin - spectrum of activity, pharmacokinetics and clinical applications. Pharmacotherapy (1992) 12(3):161–173.
  • FIESE EF, STEFFEN SH: Comparison of the acid stability of azithromycin and erythromycin A. I Antimicrob. Chemother (1990) 25(Suppl. A):39–47.
  • CARBON C, POOLE MD: The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. J. Chemother: (1999) 11(2):107–118.
  • PERITI P, MAZZIE T, MINI E, NOVELLI A: Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophys-iological states. J. Clin. Pharmacokinet. (1989) 16:193–214.
  • RETSEMA JA, GIRARD AE, GIRARD D, MILISEN WB: Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo. Antimicrob. Chemother. (1990) 25(Suppl. A):83–89.
  • CORNISH P: The new macrolides: azithromycin and clarithromycin. Clin. Clin. Pharmacol (1995) 2(4):153–166.
  • FOULDS G, SHEPARD RM, JOHNSON RB: The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. (1990) 25(Suppl. A):73–82.
  • GIRARD AE, GIRARD A, ENGLISH AR et al.: Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob. Agents Chemother. (1987) 31:1948–1954.
  • COOPER MA, NYE K, ANDREWS JM et al.: The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin." Antimicrob. Chemother. (1990) 26:533–538.
  • THAKKER KM, CARIDI F, POWELL M, CHUNG M: Multiple dose pharmaco-kinetics of azithromycin following 1 hour intravenous infusions in hospitalized patients with community-acquired pneumonia. Program Abstr: Intersci. Conf. Antimicrob. Agents Chemother: (1997) 37: 24.
  • GLADUE RP, SNIDER ME: Intracellularaccumulation of azithromycin by cultured human fibroblasts. Antimicrob. Agents Chemother. (1990) 34:1056–1060.
  • LALAK NJ, MORRIS DL: Azithromycin clinical pharmacokinetics. Clin. Pharmacokinet. (1993) 25:370–374.
  • BERMUDEZ LE, INDERLIED C, YOUNG LS: Stimulation with cytokines enhances penetration of azithromycin into human macrophages. Antimicrob. Agents Chemother. (1991) 35:2625–2629.
  • GLADUE RP, BRIGHT GM, ISAACSON RE, NEWBORG MF: In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob. Agents Chemother: (1989) 33:277–282.
  • PISCITELLI SC, DANZIGER LH, RODVOLD KA: Clarithromycin and azithromycin: new macrolide antibiotics. Clin. Pharm. (1992) 11:137–152.
  • WHITMAN MS, TUNKEL AR: Azithromycin and clarithromycin: overview and comparison with erythromycin. Infect. Cont. Hosp. Epidemiol (1992) 13(6):357–368.
  • CHU S, DEATON R, CAVANAUGH J: Absolute bioavailabity of clarithromycin after oral administration in humans. Antimicrob. Agents Chemother. (1992) 36:1147–1150.
  • NEU HC: The development of macrolides: clarithromycin in perspective. J. Antimicrob. Chemother: (1991) 27(Suppl. A):1–9.
  • FERRERO JL, BOPP BA, MARSH KC, QUIGLEY SC, JOHNSON MJ, ANDERSON DJ et al.: Metabolism and disposition of clarithromycin in man. Drug Metab. Dispos. (1990) 18:441–446.
  • LEBEL M: Clinical pharmacokinetics of clarithromycin. Can. J. Infect. Dis. (1993) 4(Suppl. A):10A–12A.
  • CHU S, PARK Y, LOCKE C, WILSON DS, CAVANAUGH JC: Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial. Clin. Pharmacol (1992) 32:32–36.
  • MACLEOD C, SCHOTZINGER RJ, VANHOVE GE BACHAND RT: Pharmacokinetics and safety of a once-daily clarithromycin formulation. Advances Ther (1999) 16:1–12.
  • PERITI P, MAZZEI T: Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen. J. Chemother: (1999) 11:11–27.
  • HARDY DJ, GUAY DR, JONES RN: Clarithromycin, a unique macrolide: a pharmacokinetic, microbiological and clinical overview. Diagn. Microbic] Infect. Dis. (1992) 15:39–53.
  • CHU SY, GRANNEMAN GR, PICHOTTA PJ, DECOURT JP, GIRAULT J, FOURTILLAN JB: Effect of moderate or severe hepatic impairment on clindamycin. Antimicrob. Agents Chemother. (1988) 32:752–754.
  • KOHNO Y, YOSHIDA H, SUWA T, SUGA T: Comparative pharmacokinetis of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats. Antimicrob. Agent Chemother. (1989) 33:751–756.
  • KOHNO Y, YOSHIDA H, SUWA T, SUGA T: Uptake of clarithromycin by rat lung cells. J. Antimicrob. Chemother. (1990) 26:503–513.
  • KOHNO Y, OHTA K, SUWA T, SUGA T: Autobacteriographic studies of clarithromycin and erythromycin in mice. Antimicrob. Agent Chemother. (1990) 34:562–567.
  • SUWA T, YOSHIDA H, FUKUSHIMA K, NAGATE T: Metabolic fate of TE-031 (A-56268) I. Comparative pharmacokinetics of TE-031 and erythromycin stearate in rats and mice. Chemotherapy (1988) 36:198–204.
  • PATEL KB, XUAN D, TESSLER PR, RUSSOMANNO JH, QUINTILIANI R, NIGHTINGALE CH: Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother. (1996) 40:2375–2379.
  • BRISSON-NOEL A, TRIEU-CUOT P, COURVALIN P: Mechanism of action of spiramycin and other macrolides. Antimicrob. Chemother. (1988) 22 (Suppl. B):13–23.
  • WEISBLUM B: Inducible resistance to macrolides, lincosamides, and streptogramin type B antibiotics: the resistance phenotype, its biological diversity and structural elements that regulate expression - a review. J. Antimicrob. Chemother. (1985) 16(Suppl. A):63–90.
  • MENNINGER JR: Functional consequences of binding macrolides to ribosomes. J. Antimicrob. Chemother. (1985) 16(Suppl. A):23–34.
  • RETSEMA JA, GIRARD A, SCHELKY W et al.: Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrob. Agents Chemother. (1987) 31:1939–1947.
  • BARRY AL, JONES RN, THORNBERRY C: In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin and clarithromycin pharmacokinetics. j Clin. Pharmacol. (1993) 33:480–485.
  • NAIK S, RUCK R: In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob. Agents Chemother. (1989) 33:1614–1616.
  • EDNIE LM, VISALLI MA, JACOBS MR48. et al.: Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. Antimicrob. Agent Chemother. (1996) 40:1950–1952.
  • HARDY DJ, HENSEY DM, BEYER JM,VOJTKO C, MCDONALD EJ, FERNANDES PB: Comparative in vitro activities of new 14-,15-, and 16-membered macrolides. Antimicrob. Agents Chemother. (1988) 32:1710–1719.
  • FERNANDES PB, HARDY DJ: Comparative in vitro potencies of nine new macrolides. Drugs Exp. Clin. Res. (1988) 14:445–451.
  • GORDILLO ME, SINGH KV, MURRAY BE: In vitro activity of azithromycin against bacterial enteric pathogens. Antimicrob. Agent Chemother.. (1993) 37:1203–5.
  • FERNANDES PB, BAILER R, SWANSON R et al.: In vitro and in vivo evaluation of A-56269 (TE-031), a new macrolide. Antimicrob. Agents Chemother. (1986) 30(6):865–873.
  • HARDY D, SWANSON RN, RODE R et al.: Enhancement of the in vitro and in vivo activities of clarithromycin against Hemophillus influenzae by 14 hydroxy-clarithromycin, its major metabolite in humans. Antimicrob. Agent Chemother. (1990) 34:1407–1413.
  • JORGENSEN JH, MAHER LA, HOWELL AW: Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae. Antimicrob. Agent Chemother. (1991) 35:1524–1526.
  • FELMINGHAM D, GRUNEBERG RN: Comparative in vitro activity of 16 antimicrobials against 5442 community-acquired, lower respiratory tract pathogens: the Alexander Project, 1997. Proceedings of the 36th IDSA, Denver, USA (1998):198.
  • BALLOW CH, JONES RN, JOHNSON DM, DEINHART JA, SCHENTAG JJ, and the SPAR STUDY GROUP: Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 90 medical centers in the USA. Diagn. Microbiol. Infect. Dis. (1997) 29:173–186.
  • CHEN DK, McGEER A, DE AZAVEDOJ, LOW DE: Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl. J. Med. (1999) 341:233–239.
  • BLONDEAU JM, VAUGHAN D, LASKOWSKI R, BORSOS S and the CANADIAN ANTIMICROBIAL STUDY GROUP: Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents. Internat. .1. Antmicrob. Agents (2001) 117:457–464.
  • GDOERN GV, HEILMANN KP, HUYNH HK, RHOMBERG PR, COFFMAN SL, BRUEGGEMANN AB: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. (2001) 45:1721–1729.
  • HOBAN DJ, WIERZBOWSKI AK, NICHOL K, ZHANEL GG: Macrolide-resistant Streptococcus pneumoniaein Canada during 1998-1999: prevalence of met(A) and erm(B) and susceptibilities to ketolides. Antimicrob. Agents Chemother. (2001) 45(7):2147–2150.
  • EADY EA, ROSS JI, COVE JH: Multiple mechanisms of erythromycin resistance. J. Antimicrob. Chemother. (1990) 26:461–465.
  • DOERN GV, BRUEGGEMANN AB, HUYNH H, WINGERT E, RHOMBERG P: Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-1998. Emerg. Infect. Dis. (1999) 5:757–765.
  • SHORTRIDGE VD, DOERN GV, BRUEGGEMANN AB, BEYER JM, FLAMM RK: Prevalence of macrolide resistance mechanims in Streptorcoccu pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994–1995. Clin. Infect. Dis. (1999) 29:1186-1188. WAITES K, JOHNSON C, BANKS S et al.: Use of clindamycin disks to predict high-level macrolide resistance in Streptococcu pneumoniae. 9th European Congress of Clinical Microbiology and Infectious Disease; Berlin, Germany (21–24 March 1999). Poster 9878. HOPKINS S: Clinical toleration and safety of azithromycin in adults and children. Rev Contemp. Pharmacother. (1994) 5:383–389.
  • GUAY DR, PATTERSON DR, SEIPMAN N, CRAFT JC: Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Sal (1993) 8:350–364.
  • LEVENSTEIN JH: Clarithromycin versus penicillin in the treatment of streptococcal pharyngitis. j. Antimicrob. Chemother: (1991) 27\(Suppl. 467–74.
  • BACHAND RT: A comparative study of clarithromycin and penicillin VK in the treatment of outpatients with streptococcal pharyngitis. j. Antmicrob. Chemother: (1991) 27\(Suppl. 475–82.
  • BACHAND RT: Comparative study of clarithromycin and ampicillin in the treatment of patients with acute exacerbations of chronic bronchitis.' Antimicrob. Chemother. (1991) 27\(Suppl. 491–100.
  • HOPKINS S: Clinical toleration and safety of azithromycin. Amer: J. Med. (1991) 91 (Suppl. 3A):405–455.
  • DUNN CJ, BARRADELL LB: Azithromycin: a review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs (1996) 51(3):483–505.
  • GUAY DRP: Pharmacokinetics of new macrolides. Infect. Med. (1992) 9\(Suppl. 431–38.
  • ANDERSON G, ESMONDE TS, COLES S, MACKLIN J, CARNEGIE C: A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. Antimicrob. Chemother. (1991) 27\(Suppl. 4117–124.
  • WALLACE RJ Jr, BROWN BA, GRIFFITH DE: Drug intolerance to high-dose clarithromycin among elderly patients. Diagn. Microbiol Infect. Dis. (1993) 16:215–221.
  • YEW WW, CHAU CH, LEE J, LEUNG CW: Cholestatic hepatitis in a patient who received clarithromycin therapy for a Mycobacterium chelonae lung infection (letter). Clin. Infect. Dis. (1994) 18:1025–1026.
  • SHAHEEN N, GRIMM IS: Fulminant hepatic failure associated with clarithromycin. Jim. .1 Castroenterol (1996) 91:394–395.
  • LIVIU L, YAIR L, YEHUDA S: Pancreatitis induced by clarithromycin (letter). Ann. Intern. Med. (1996) 125:701.
  • PIJPERS E, VAN RIJSWIJK RE, TAKX-KOHLEN B, SCHREY G: A clarithro- mycin-induced myasthenic syndrome. Clin. Infect. Dis. (1996) 22:175–176.
  • AMSDEN GW: Erythromycin, clarithromycin and azithromycin: are the differences real? Clin. Therapeu. (1996) 18(1):56–72.
  • EISENBERG E, BARZA M: Azithromycin and clarithromycin. Carr: Clin. Top. Infect. Dis. (1994) 14:52–79.
  • PERITI P, MAZZEI T, MINI E, NOVELLI A: Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokinet. (1992) 23:106–131.
  • WATKINS VS, POLK RE, STOTKA JL: Drug interactions of macrolides: emphasis on dirithromycin. Ann. Pharmacother. (1997) 31:349–356.
  • LUDDEN TM: Pharmacokinetic interactions of the macrolide antibiotics. Clin. Pharmacokinet. (1985) 10:63–79.
  • NAWARSKAS JJ, MCCARTHY DM, SPINLER SA: Digoxin toxicity secondary to clarithromycin therapy. Ann. Pharmacother: (1997) 31:864–866.
  • SPICER ST, LIDDLE C, CHAPMAN JR, BARCLAY P, NANKIVELL BJ, THOMAS P et al.: The mechanism of cyclosporine toxicity induced by clarithromycin. Br. Clin. Pharmacol (1997) 43:194–196.
  • BROWN BA, WALLACE RJ JR, GRIFFITH DE, WARDEN R: Clarithromycin-associated digoxin toxicity in the elderly. Clin. Infect. Dis. (1997) 24:92–93.
  • PAAR D, TERJUNG B, SAUERBRUCH T: Life-threatening interaction between clarithromycin and disopyramide (letter). Lancet (1997) 349:326–327.
  • GRAU E, REAL E, PASTER E: Interaction between clarithromycin and oral anticoagulants (letter). Ann. Pharmacother. (1996) 30:1495–1496.
  • GILLUM JG, ISRAEL DS, SCOTT RB, CLIMO MW, POLK RE: Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers. Antimicrob. Agents Chemother: (1996) 40:1715–1716.
  • BEDFORD TA, ROWBOTHAM DJ: Cisapride: drug interactions of clinical significance. Drug Sal (1996) 15:167–175.
  • YEATES RA, LAUFEN H, ZIMMERMANN T: Interaction between midazolam and clarithromycin: comparison with azithromycin. Int. j Clin. Pharmacol Ther (1996) 34:400–405.
  • SKETRIS IS, WRIGHT MR, WEST ML: Possible role of the intestinal P450 enzyme system in a cyclosporine-clarithromycin interaction. Pharmacotherapy (1996) 16:301–305.
  • VANCE E, WATSON-BITAR M, GUSTAVSON L, KAZANJIAN P: Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. Antimicrob. Agents Chemother. (1995) 39:1355–1360.
  • VANCE E, GUZMAN J, BITAR M, KAZANJIAN P: Clarithromycin and zidovudine pharmacokinetic study (abstract). Int. Conf. AIDS (1994) 10:201.
  • GUSTAVSON LE, CHU SY, MACKENTHUM A, GUPTA SD, CRAFT JC: Drug interaction between clarithromycin and oral zidovudine in HIV-1 infected patients (abstract). Clin. Pharmacol Ther. (1993) 53:163.
  • POLIS MA, PISCITELLI SC, VOGEL S, WITEBSKY FG, CONVILLE PS, PETTY B et al.: Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. Antimicrob. Agents Chemother. (1997) 41:1709–1714.
  • TOLTZIS P, WITTE MK, REED MD: Lower respiratory tract infections. In: Pharmacotherapy. A Pathophysiologic Approach. 3rd ed. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (Eds), Appleton and Lange, Stamford USA (1997):1995–2016.
  • NIEDERMAN MS, McCOMBS JS, UNGER AN, KUMAR A, POPOVIAN R: The cost of treating community acquired pneumonia. Clin. Ther. (1998) 20:820–837.
  • BARTLETT JG, DOWELL SF, MANDELL LA, FILE TM Jr, MUSHER DM, FINE MJ: Practice guidelines for the management of community-acquired pneumonia in adults. Clin. Infect. Dis. (2000) 31:347–382.
  • BARTLETT JG: Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices. &min. Respir. Infect. (1997) 12:329–333.
  • BARTLETT JG, BREIMAN RE MANDELL LA et al.: Community-acquired pneumonia in adults: guidelines for management. Clin. Infect. Dis. (1998) 26:811
  • AMERICAN THORACIC SOCIETY:Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. Am. Rev. Respir. Dis. (1993) 148:1418–1426.
  • VERGIC EN, YU VL: Macrofides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host. Semin. Respir: Infect. (1997) 12:322–328.
  • ”MANDELL LA, MARRIE TJ, GROSSMAN RE CHOW AW, HYLAND RH and the CANADIAN COMMUNITY-ACQUIRED PNEUMONIA WORKING GROUP: Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin. Infect. Dis. (2000) 31:383–421.
  • BALMES P, CLERC G, DUPONT B et al:Comparative study of azithromycin and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infections. Eur: Clin. Microbial. Infect. Dis. (1991) 10:437–439.
  • DARK D: Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections. Am. J. Med. (1991) 91(Suppl. 3A):315–355.
  • SCHONWALD S, GUNJACA M, KOLACNY-BABIC L et al.: Comparison of azithromycin and erythromycin in the treatment of atypical pneumonia. J. Antimicrob. Chemother: (1990) 25(Suppl. A):123–126.
  • KINASEWITZ G, WOOD RG: Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur. Clin. Microbial. Infect. Dis. (1991) 10:872–877.
  • BOHTE R, VANTWOUT JW, LOBATTO S et al: Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur: I Clin. Microbial. Infect. Dis. (1995) 14:182–187.
  • RAMIREZ J, UNOWSKY J, TALBOT GH et al.: Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clin. Ther: (1999) 21:103–117.
  • FOGARTY C, GROSSMAN C, WILLIAMS J et al.: Efficacy and safety of moxifloxacin versus clarithromycin for community-acquired pneumonia. Infect. Med. (1999) 16:748–763.
  • PATEL T, DESAI R, DUFF J et al.: Comparison of grepafloxacin with clarithromycin in the treatment of community-acquired pneumonia. In: Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 37th Annual Meeting. Washington, DC, USA (28 September-1 October 1997).
  • SULLIVAN J, GEZON D, HOPKINS W: A double-blind, randomized, multicenter study in ambulatory community-acquired pneumonia comparing trovafloxacin with clarithromycin. In: Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 37th Annual Meeting, Washington, DC, USA (28 September-1 October 1997).
  • CHIEN SM, PICHOTTA P, SIEPMAN N and the CANADA-SWEDEN CLARITHROMYCIN PNEUMONIA STUDY GROUP et al.: Treatment of community-acquired pneumonia: a multicenter, double-blind randomized study comparing clarithromycin with erythromycin. Chest (1993) 103:697–701.
  • NEU HC, CHICK TW: Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. Chest (1993) 104:1393–1399.
  • O'DOHERTY B, MULLER 0: Randomized, multicenter study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia - Azithromycin Study Group. Eur. I Clin. Microbial. Infect. Dis. (1998) 17:828–833.
  • CHARLES L, SEGRETI J: Choosing the right macrolide antibiotic: a guide to selection. Drugs (1997) 53:349–357.
  • STAHL JE, BARZA M, DESJARDIN J, MARTIN R, ECKMAN MH: Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch. Intern. Med. (1999) 159:2576–2580.
  • GLEASON PP, MEEHAN TP, FINE JM, GALUSHA DH, FINE MJ: Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch. Intern. Med. (1999) 159:2562–2572.
  • MARSTON BJ, PLOUFFE JF, FILE TM and the COMMUNITY-BASED PNEUMONIA INCIDENCE STUDY GROUP et al: Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch. Intern. Med. (1997) 157:1709–1718.
  • STEPHENSON J: Studies suggest a darker side of 'benign' microbes. JAMA (1997) 38:1873–1878.
  • TAYLOR-ROBINSON D: Infections due to species of Mycoplasma and Ureaplasma: an update. Clin. Infect. Dis. (1996) 23:671–684.
  • HAMMERSCHLAG MR: Antimicrobial susceptibility and therapy of infections caused by Chlarnydia pneumoniae. Antimicrob. Agents Chemother. (1994) 38:1873–1878.
  • TROY CJ, PEELING RW, ELLIS AG et al: Chlamydia pneumaniae as a new source of infectious outbreaks in nursing homes. JAMA (1997) 277:1214-1218. Erratum: JAMA (1997) 278:118.
  • BLONDEAU JM, TILLOTSON GS: A critical review of the changing etiology of community-acquired pneumonia and the clinical impact of antimicrobial resistance. Chest (2000) 118 (Suppl. ):5235.
  • CENTERS FOR DISEASE CONTROL AND PREVENTION: Number of selected chronic conditions per 1,000 persons, by age: United States, 1994.
  • •See [201].
  • MERTENS JCC, VAN BARNEVELD PWC, ASIN HRG et al.: Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. Antimicrob. Agents Chemother. (1992) 36:1456–1459.
  • DEABATE CA, MATHEW CP, WARNER JH, HEYD A, CHURCH D: The safety and efficacy of short course (5-day) mwdfloxacin versus azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir: Med. (2000) 94:1029–1037.
  • ANZUETO A, NIEDERMAN MS, TILLOTSON GS, and the BRONCHITIS STUDY GROUP: Etiology, susceptibility and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg BID or clarithromycin 500 mg BID. Clin. Ther: (1998) 20:885–900.
  • DEABATE CA, HERMAN-GNJIDIC Z, ANEIRO L, HAVERSTOCK D, CHURCH D: Moxifloxacin in acute exacerbations of chronic bronchitis - a bacteriological meta-analysis. 21st International Congress of Chemotherapy Birmingham, England. (4–7 July 1999). Poster P497.
  • NOTARIO G, SIEPMAN N, DEVCICH K, GUAY DRP: Comparative safety and efficacy of clarithromycin and three oral cephalosporins in the treatment of outpatients with bacterial bronchitis. Curr. Ther. Res. (1993) 54:628–640.
  • ANZUETO A, JENKINSON SG and the CLARITHROMYCIN CHRONIC BRONCHITIS STUDY GROUP: Safety and efficacy of clarithromycin versus cefuroxime axetil in the treatment of acute bacterial exacerbation of chronic bronchitis. Immunol Infect. Dis. (1993) 3:231–237.
  • POZZI E, GROSSI E, PECORI A and the AZITHROMYCIN RESEARCH GROUP: Azithromycin versus clarithromycin in the treatment of acute exacerbations of chronic bronchitis. Carr. Therapeu. Res. (1994) 55(7):759–764.
  • O'BRIEN KL, DOWELL SF, SCHWARTZ B, MARCY SM, PHILLIPS WR, GERBER MA: Acute sinusitis-principles of judicious use of antimicrobial agents. Pediatrics (1998) 101:174–177.
  • CASIANO RR: Azithromycin and amoxicillin in the treatment of acute maxillary sinusitis. Am. j Med. (1991) 91(Suppl. A):83–90.
  • CALHOUN KH, HOKANSON JA: Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis. Arch. Fam. Med. (1993) 2:837–840.
  • ADELGLASS J, JONES TM, RUOFF Get al.: A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis. Pharmacotherapy (1998) 18:1255–1263.
  • DUBOIS J, SAINT-PIERRE C, TREMLAY C: Efficacy of clarithromycin versus amoxicillin/clavulanate in the treatment of acute maxillary sinusitis. Ear, Nose, Throat (1993) 72:804–810.
  • HOOTEN TM: A comparison of azithromycin and penicillin V for the treatment of streptococcal pharyngitis. Am. J. Med. (1991) 91(Suppl. A):23–26.
  • GOOCH WM, GAN VN, CORDER WT et al.: Clarithromycin and cefaclor suspensions in the treatment of acute otitis media in children. Pediatr. Infect. Dis. (1993) 12\(Suppl. 3):5128–133.
  • SCHROCK CG: Clarithromycin versus penicillin in the treatment of streptococcal pharyngitis. J. Earn. Practice (1992) 35:622–626.
  • BENSON V, MARANO MA: Current estimates from the National Health Interview Survey, 1995. National Center for Health Statistics. Vital Health Star (1998)10(199).
  • McCARTY JM, PHILLIPS A, WIISANEN R: Comparative safety and efficacy of clarithromycin and amoxicillin/clavulanate in the treatment of acute otitis media in children. Pediatr. Infect. Dis. 1. (1993) 12:S122–S127.
  • ASPIN MM, HOBERMAN A, MCCARTY J et al.: Comparative study of the safety and efficacy of clarithromycin and amoxicillin-clavulanate in the treatment of acute otitis media in children. I. Pediatr. (1994) 125:136–141.
  • RAMET J: Comparative safety and efficacy of clarithromycin and azithromycin suspensions in the short course treatment of children with acute otitis media. Clin. Drug Invest. (1995) 9:61–66.
  • MALLORY SB: Azithromycin compared with cephalexin in the treatment of skin and skin structure infections. Am. I. Med. (1991) 91(Suppl. 3A):365–395.
  • KIANI R: Double-blind, double-dummy comparison of azithromycin and cephalexin in treatment of skin and skin structure infections. Ear: Clin. Microbial. Infect. Dis. (1991) 10:880–884.
  • PARISH LC: Clarithromycin in the treatment of skin and skin structure infections: two multicenter clinical studies. Int. J. Dermatol (1993) 32:528–532.
  • MCNULTY CA, DENT JC: Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents. Ear: J. Clin. Microbial. Infect. Dis. (1988) 7:566–569.
  • HULTEN K, CARS 0, HJELM E, ENGSTRAND L: In vitro activity of azithromycin against intracellular Helicobacter pylori .1. Antimicrob. Chemother. (1996) 37:483–489.
  • GLUPCZYNSKI Y, BURETTE A: Failure of azithromycin to eradicate Campylobacter pylori from the stomach because of acquired resistance during treatment. Am. .1. Castroenterol (1990) 85:98–99.
  • PETERSON WL, GRAHAM DY, MARSHALL B et al.: Clarithromycin as monotherapy for eradication of Helicobacter pylori. a randomized, double-blind trial. Am.j Castroenterol (1993) 88:1860–1864.
  • SOLL AH for the PRACTICE PARAMETERS COMMITTEE OF THE AMERICAN COLLEGE OF GASTROENTEROLOGY: Medical Treatment of Peptic Ulcer Disease: Practice Guidelines. I. Am. Merl Assoc. (1996) 275:622–629.
  • AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS: ASHP therapeutic position statement on the identification and treatment of Helicobacter pylori-associated peptic ulcer disease in adults. Am. j Health Syst. Pharm. (2001) 58:331–337.
  • O'BRIEN B, GOEREE R, HAFEEZ MOHAMED A, HUNT R: Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch. Intern. Med. (1995) 155:1958–1964.
  • MARTIN DH, MROCZKOWSKI TF, DALU ZA et al.: A controlled trial of a single dose of azithromycin for the treatment of Chlamydial urethritis and cervicitis. N Engl. I. Med. (1992) 327:921–925.
  • LASSUS A: Comparative studies of azithromycin in skin and soft tissue infections and sexually transmitted infections by Neisseria and Chlamydia species. Antimicrob. Chemother. (1990) 25(Suppl. A):115–121.
  • JOHNSON RB: The role of azalide antibiotics n the treatment of Chlamydia. Am. J. Obstet. Cynecol (1991) 64:1794–1796.
  • IVES DV, DAVIS RB, CURRIER JS: Impact of clarithromycin and azithromycin on patterns of treatment of survival among AIDS patients with disseminated Mycobacterium avium complex. AIDS (1995) 9:261–266.
  • KOLETAR SL, BERRY AJ, CYNAMON MH et al.: Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients. Antimicrob. Agent Chemother. (1999) 43:2869–2872.
  • CHAISSON RE, KEISER P, PIERCE Met al.: Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patiens with HIV infection. AIDS (1997) 11:311–317.
  • DAUTZENBERG B, TRUFFFOT-PERNOT C, HAZEBROUCQ J et al.: A randomized comparison of two clarithromycin doses for treatment of Mycobacterium avian] complex infections. Infection (1997) 25:16–21.
  • DUNNE M, FESSEL J, KUMAR P et al.: A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avian] infection in patients with human immunodeficiency virus. Clin. Infect. Dis. (2000) 31:1245–1252.
  • CENTER FOR DISEASE CONTROL AND PREVENTION: 1997 USPHS/ IDSA Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb. Mort. Wkly Rep. (1997) 46:1–46.
  • PIERCE M, CRAMPTON S, HENRY D et al.: A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avian] complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl. J. Med. (1996) 335:384–391.
  • DEVER LL, JORGENSEN JH, BARBOUR AG: Comparative in vitro activities of clarithromycin, azithromycin and erythromycin against Borrelia burgdorferi Antimicrob. Agents Chernother. (1993) 37:1704–1706.
  • JOHNSON RC, KODNER C, RUSSELL M, GIRARD D: In vitro and in vivo susceptibility of Borrelia burgdorferito azithromycin. I Antimicrob. Chernothec (1990) 25(Suppl. A):33–38.
  • STRIE F, MARASPIN V, LOTRIC-FURLAN S, RUZIC-SABIJIC E, CIMPERMAN J: Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. Infection (1996) 24:64–68.
  • WEBER K, WILSKE B, PREAC-MURSIC V, THURMAYR R: Azithromycin versus penicillin V for t he treatment of early Lyme borreliosis. Infection (1993) 21:367–372.
  • LUFT BJ, DATTWYLER RJ, JOHNSON RC et al: Azithromycin compared with amoxicillin in the treatment of erythema migrans: a double-blind, randomized, controlled trial. Ann. Intern. Med. (1996) 124:785–791.
  • DATTWYLER RJ, GRUNWALDT E, LUFT BJ: Clarithromycin in treatment of early Lyme disease: a pilot study. Antimicrob. Agents Chernother: (1996) 40:468–469.
  • ALDER J, MITTEN M, JARVIS K, GUPTA P, CLEMENT J: Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo. Antimicrob. Agents Chernother.. (1993) 37:1329–33.
  • PREAC-MURSIC V, WILSKE B, SCHIERZ G, SUSS E, GROSS B: Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi Eur. Clin. Microbial. Infect. Dis. (1989) 8:651–3.
  • CANTIN L, CHAMBERLAND S: In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondd Antimicrob. Agents Chernother: (1993) 37:1993–1996.
  • HARDY WD, BOZZETTE S, SAFRIN S et al.: Results from recent therapeutic trials for opportunistic infections from the United States. AIDS (1994) 8:S15.
  • GUERRA LG, NEIRA CJ, BOMAN D, HO H, CASNER PR, ZUCKERMAN M et al.: Rapid response of AIDS-related bacillary angiomatosis to azithromycin. Clin. Infect. Dis. (1993) 17:264–266.
  • CHIA JK, NAKATA MM, LAMI JL, PARK SS, DING JC: Azithromycin for the treatment of cat-scratch disease. Clin. Infect. Dis. (1998) 26:193–194.
  • HOQUE S, WEIR A, FLUCK R, CUNNINGHAM J: Rhodococcus equi in CAPD-associated peritonitis treated with azithromycin. Nephrol Dial. Transplant. (1996) 11:2340–2341.
  • MASCELLINO MT, IONOA E, PONZO R, MASTROIANNI CM, DELIA S: Infections due to Rhodococcus equiin three HIV-infected patients: microbiological findings and antibiotic susceptibility. Int. J. Clin. Phanncol. Res. (1994) 14:157–163.
  • HICKS P, ZWIENER RJ, SQUIRES J, SAVELLV: Azithromycin therapy for Cryptosporidium par vain infection in four children infected with human immunodeficiency virus. J. Pediatr. (1996) 129:297–300.
  • BLANSHARD C, SHANSON DC, GAZZARD BG: Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis. Int. J. STD AIDS (1997) 8:124–129.
  • GIRGIS NI, FRENCK RW, SULTAN Y: Single dose azithromycin compared to a four dose rifampin regimen for the eradication of meningococcal nasopharyngeal carriage (abstract). Program Abstr. Intersci. Conf. Antimicrob. Agents Chernother: (1997) 37: 364.
  • ANDERSEN SL, AGER A, MCGREEVY P, SCHUSTER BG, WESCHE D, KUSCHNER R et al.: Activity of azithromycin as a blood schizonticide against rodent and human plasmodia in vivo. Am. J. Bop. Med. Hyg. (1995) 52:159–161.
  • GINGRAS BA, JENSEN JB: Activity of azithromycin (CP-62,993) and erythromycin against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium fakiparum in vitro. Am. J. Bop. Med. Hyg. (1992) 47:378–382.
  • BARZA M, EISENBERG E: Clarithromycin and azithromycin. Infect. Dis. Clin. Pract. (1996) 5:291–302.
  • LACASSIN F, SCHAFFO D, PERRONNE C, LONGUET P, LEPORT C, VILDE JL: Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immuno-deficiency virus. Antimicrob. Agents Chernother: (1995) 39:276-277. Letter.
  • FERNANDEZ-MARTIN J, LEPORT C, MORIAT P, MEYOHAS MC, CHAUVIN JP, VILDE JL: Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob. Agents Chernother. (1991) 35:2049–2052.
  • RAFFI F, STRUILLOU L, NININ E, RELIQUET V, BILLAUD E, MLPIED B: Breakthrough cerebral toxoplasmosis in patients with AIDS who are being treated with clarithromycin. Clin. Infect. Dis. (1995) 20:1076-1077. Letter
  • BASS JW, VINCENT JM, PERSON DA: The expanding spectrum of Bartonella infections. II: cat-scratch disease. Pediatc Infect. Dis. J. (1997) 16:163–179.
  • DAJANI AS, TAUBERT KA, WILSON W et al.: Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA (1997) 277:1794–1801.
  • ROUSE MS, STECKELBERG JM, BRANDT CM, PATEL R, MIRO JM, WILSON WR: Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. Antimicrob. Agents Chernothec (1997) 41:1673–1676.
  • BLONDEAU JM, VAUGHAN D: A rev-iew of antimicrobial resistance in Canada. Can. J. Microbial. (2000) 46:867–877.
  • BLONDEAU JM: Community-acquired respiratory tract pathogens and increasing antimicrobial resistance. J. Infect. Dis. Pharmacother. (2000) 4\(Suppl. 2).
  • THORNSBERRY C, SAHM DF, KELLY LJ, CRITCHLEY IA, JONES ME, EVANGELISTA AT, KARLOWSKY JA: Regional Trends in Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae, Haemophilus iniluenzae, and Moraxella catarrhalisin the United States: Results from the TRUST Surveillance Program, 1999-2000. Clinical Infectious Diseases. (2000) 34:S4–S16.
  • AMERICAN THORACIC SOCIETY: Guidelines for the management of adults with community-acquired pneumonia. Am. Respir. Grit. Care. Med. (2001) 163:1730–1754.
  • WAUGH MA: Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhoea in men and women. Antimicrob. Chemother. (1993) 31(Suppl. E):193.
  • HANDSFIELD HH, DALU ZA, MARTIN DH et al Multicenter trial of single-dose azithromycin versus ceftriaxone in the treatment of uncomplicated gonorrhea. S. Tansm. Dis. (1994) 21:107.
  • CENTERS FOR DISEASE CONTROL AND PREVENTION: 1998 guidelines for treatment of sexually transmitted diseases. MMWR Morb. Mort. Wkly Rep. (1998) 47(RR-1):1.
  • HOBAN DJ, DOERN, GV, FLUIT AC, ROUSSEL-DELVALLEZ M, JONES RN: Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus iniluenzae, and Moraxella catarrhalixin the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin. Infect. Dis. (2001) 32\(Suppl. 2):S81–93.
  • HO PL, QUE TL, TSANG DN, NG TK, CHOW KH, SETO WH: Emergence of Fluoroquinolone Resistance among Multiply Resistant Strains of Streptococcus pneumoniae in Hong Kong. Antimicrobial Agents and Chemotherapy (1999) 43(5):1310–1313.
  • DOERN GV, HEILMANN KP, HUYNH HK, RHOMBERG PR, COFFMAN SL, BRUEGGEMANN AB: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1990-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. (2001) 45(6):1721–1729.
  • SAHM DF, KARLOWSKY JA, KELLY LJ et al.: Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-Year Longitudinal Analysis..Antimicrob. Agents Chemother. (2001) 45(4):1037–1042.
  • ZHANEL GG, KARLOWSKY JA, PALATNICK LP et al.: Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study. Antimicrob. Agents Chemother. (1999) 43(10):2504–2509.
  • LOW DE, DE AZAVEDO J, WEISS K et a/.: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob. Agents Chemother. (2002) 46(5):1295–1301.
  • ENGBERG J, AARESTUP FM, TAYLOR DE, GERNER-SMIDT P, NACHAMKIN I: Quinolone and macrolide resistance in Campylobacter jtjuni and C. colt. resistance mechanisms and trends in human isolates. Emerg. Infect. Dis. (2001) 7(1):24–34.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.